These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31479414)

  • 1. Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas.
    Argadal OG; Mutlu M; Ak Aksoy S; Kocaeli H; Tunca B; Civan MN; Egeli U; Cecener G; Bekar A; Taskapilioglu MO; Tekin C; Tezcan G; Tolunay S
    Bosn J Basic Med Sci; 2020 Feb; 20(1):63-69. PubMed ID: 31479414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexistence of TERT C228T mutation and MALAT1 dysregulation in primary glioblastoma: new prognostic and therapeutic targets.
    Ak Aksoy S; Mutlu M; Tunca B; Kocaeli H; Taskapilioglu MO; Bekar A; Tekin C; Argadal OG; Civan MN; Kaya İS; Ocak PE; Tolunay S
    Neurol Res; 2021 Nov; 43(11):916-925. PubMed ID: 34210246
    [No Abstract]   [Full Text] [Related]  

  • 3. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
    Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
    Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
    Shin JH; Lee YS; Hong YK; Kang CS
    J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
    Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q
    Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
    Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Immunohistochemical Expression of ALK-1 in Gliomas, WHO Grade 4 and Its Correlation with IDH1-R132H Mutation Status.
    Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of TERT mutation in adults with primary glioblastomas. Preliminary results].
    Zolotova SV; Anoshkin KI; Absalyamova OV; Makashova ES; Belyashova AS; Telysheva EN; Golanov AV
    Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(3):33-40. PubMed ID: 35758076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
    Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
    J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
    Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
    J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
    Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
    de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
    Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.
    Catteau A; Girardi H; Monville F; Poggionovo C; Carpentier S; Frayssinet V; Voss J; Jenkins R; Boisselier B; Mokhtari K; Sanson M; Peyro-Saint-Paul H; Giannini C
    Acta Neuropathol Commun; 2014 Jun; 2():58. PubMed ID: 24889502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O
    Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
    Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
    Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
    Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.